🔴 Summit Therapeutics is trading 4.5% down today alongside declines in major indexes

Summit Therapeutics is trading at $17.14, down 4.51%, amid broader market weakness; the exact cause of the decline is not established.

• No new Summit-specific catalyst surfaced in the October 8 search. Recent AstraZeneca and Daiichi Sankyo collaboration news dates to October 2, not October 8.
• The Nasdaq is down 0.55% and the S&P 500 is down 0.32%, indicating broader pressure without establishing the decline’s exact cause.
• Volume and other activity details were not available in the provided price context.